Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis

[1]  Hong-guo Zhao,et al.  Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. , 2021, The Lancet. Haematology.

[2]  D. Gómez-Almaguer,et al.  Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center , 2020, Annals of Hematology.

[3]  Hong-guo Zhao,et al.  High‐dose dexamethasone plus recombinant human thrombopoietin vs high‐dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial , 2020, American journal of hematology.

[4]  H. de Haard,et al.  Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia , 2019, American journal of hematology.

[5]  E. Neufeld,et al.  Second‐line treatments in children with immune thrombocytopenia: Effect on platelet count and patient‐centered outcomes , 2019, American journal of hematology.

[6]  B. Chong,et al.  Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies , 2019, British journal of haematology.

[7]  L. F. Allen,et al.  Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia , 2018, British journal of haematology.

[8]  C. Uiterwaal,et al.  Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial. , 2018, Blood.

[9]  Jiří Mayer,et al.  Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials , 2018, American journal of hematology.

[10]  C. Polprasert,et al.  A Randomized Multicenter Trial Comparing Low-Dose Prednisolone Versus Observation for Prevention of Recurrences in Adult Immune Thrombocytopenia , 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[11]  D. Cines,et al.  Controversies in the treatment of immune thrombocytopenia , 2016, Current opinion in hematology.

[12]  A. Raj,et al.  Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study , 2016, The Lancet.

[13]  V. Blanchette,et al.  A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Determine the Effect of Romiplostim on Health‐Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents , 2016, Pediatric blood & cancer.

[14]  M. Hou,et al.  High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. , 2016, Blood.

[15]  J. Bussel,et al.  Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial , 2015, The Lancet.

[16]  J. Bussel,et al.  Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. , 2015, The Lancet. Haematology.

[17]  J. P. Braga,et al.  Helicobacter pylori infection & immune thrombocytopenic purpura in children and adolescents: A randomized controlled trial , 2015, Platelets.

[18]  A. Waage,et al.  Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[19]  Hong-guo Zhao,et al.  A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. , 2015, Blood.

[20]  B. van der Holt,et al.  Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients , 2015, Haematologica.

[21]  J. Bussel,et al.  Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia , 2014, American journal of hematology.

[22]  L. Kjeldsen,et al.  Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. , 2013, Blood.

[23]  G. Gaedicke,et al.  Immune thrombocytopenia in children and adults: what’s the same, what’s different? , 2011, Haematologica.

[24]  M. Crowther,et al.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.

[25]  J. Bussel,et al.  Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study , 2011, The Lancet.

[26]  R. Fanin,et al.  Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. , 2010, Blood.

[27]  R. Hodgson,et al.  Schizophrenia and breast cancer incidence A systematic review of clinical studies , 2009, Schizophrenia Research.

[28]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[29]  Georgia Salanti,et al.  Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.

[30]  A. Cipriani,et al.  What is a risk ratio? , 2007, Epidemiologia e Psichiatria Sociale.

[31]  F. Dentali,et al.  Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura , 2007, Annals of Internal Medicine.

[32]  J. Leonard,et al.  The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura , 2004, British journal of haematology.

[33]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[34]  G. Guyatt,et al.  Interpreting treatment effects in randomised trials , 1998, BMJ.

[35]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.